This month, AbbVie gave iStar Medical an upfront cash payment to continue the development of its glaucoma devices, with the deal also granting AbbVie the option to purchase iSTAR outright for nearly half a billion dollars. (Also see "Minute Insight: AbbVie Bets Big On Glaucoma Market With iSTAR Purchase Deal" - Medtech Insight, 20 July, 2022.)
In diagnostics, both Delfi Diagnostics and LumiraDx raised heft sums of cash through a series B round and a public share offering, respectively.